Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
Retrieved on:
Tuesday, April 2, 2024
COVID19, COVID, Trawsfynydd, Pfizer, Drug, Novartis, General partnership, Patient, CYP, Oseltamivir, CDK, Aes, Ritonavir, SARS-CoV-2, Delta, Infection, Viral disease, Omicron, Therapy, OrbiMed, Safety, Pharmacokinetics, Toxicology, Lilly, Bone marrow suppression, CSO, GLP, Mergers and acquisitions, Pharmaceutical industry
Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)
Key Points:
- Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)
Companies to host joint webcast, April 2, 2024 at 8:30 a.m. - Under the terms of the agreement, Onconova acquired 100% of Trawsfynydd’s outstanding equity interests.
- These proceeds will be used to advance the Traws’ programs through multiple clinical data catalysts and complete the dose ranging study for narazaciclib.
- Topline data are expected H2 2024
Phase 2 study planned to be initiated in H2 2024.